Q-Line Biotech Limited H1 FY27 revenue rises 5.83%, PAT falls 8.06%

For H1 FY27 ended September 30, 2026, Q-Line Biotech Limited reported consolidated revenue of ₹152.18 crore, up 5.83% year-on-year, while profit after tax declined 8.06% to ₹19.60 crore. EBITDA increased 10.02% to ₹39.57 crore and the EBITDA margin improved to 26.00%.

What did Q-Line Biotech Limited report for H1 FY27?

Q-Line Biotech Limited reported a rise in revenue and operating profit for the half year ended September 30, 2026, although net profit was lower than the corresponding period a year earlier. The diagnostic test kits, reagents and laboratory equipment manufacturer recorded total revenue of ₹152.18 crore, compared with ₹143.80 crore in H1 FY26.

EBITDA rose to ₹39.57 crore from ₹35.97 crore, outpacing the pace of revenue growth. This lifted the EBITDA margin by 99 basis points to 26.00%, from 25.01% in H1 FY26. Profit before tax, however, was marginally lower at ₹25.94 crore against ₹26.25 crore in the prior-year half.

Profit after tax stood at ₹19.60 crore, compared with ₹21.32 crore in H1 FY26. The company said its operating performance reflected sustained demand for its products, a wider market presence and continued operational focus. The disclosed numbers are consolidated results for the six-month period.

How were Q-Line's H1 FY27 results approved?

Q-Line's Board of Directors approved the unaudited standalone and consolidated financial results at its meeting held on November 12, 2026. The approval covered the statements of assets and liabilities and cash flow statements for the half year ended September 30, 2026.

Before the board meeting, the Audit Committee recommended the financial results along with the limited review reports issued by the statutory auditor. The company also made the required declaration under Regulation 33(2) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The company had informed the NSE on November 5, 2026 that its board would consider the half-yearly results. The results were approved 43 days after the end of the September half year. The disclosure formally updates investors on the financial position of the company for the first six months of FY27.

How has Q-Line used its IPO proceeds through September 2026?

Q-Line had utilised ₹122.34 crore of its ₹214.48 crore IPO proceeds as of September 30, 2026, according to a Monitoring Agency Report issued by Care Ratings Limited. This represents the utilisation reported by the company for the period covered by the report.

The balance of ₹92.14 crore remained unutilised at the reporting date. Q-Line said the unutilised amount was parked in fixed deposits with IndusInd Bank and HDFC Bank. The company disclosed the monitoring report alongside its half-yearly financial updates.

The monitoring agency report is relevant because it provides a third-party review of how the company has deployed the money raised through its public issue. It also identifies the amount that remained available for deployment at the end of the half year.

What do the results mean for investors and operations?

The H1 FY27 figures show that Q-Line expanded revenue and improved operating margin, but the improvement did not translate into higher profit after tax. EBITDA grew faster than revenue, while profit before tax declined 1.17% and profit after tax fell 8.06% from the year-earlier period.

For investors, the contrast between operating growth and lower net profit is a key feature of the half-year result. The disclosed figures do not provide a detailed item-wise explanation for the decline in profit after tax, so the financial release should be assessed on the numbers reported rather than assumptions about the cause.

The company operates in India's diagnostic products and laboratory equipment segment, where product demand and operating execution affect revenue and margins. Its FY26 consolidated revenue was ₹341.74 crore, EBITDA was ₹98.05 crore and profit after tax was ₹56.71 crore, providing the full-year comparison disclosed alongside the H1 results.

Q-Line's separate disclosure on IPO proceeds also matters for shareholders because a substantial portion of the issue funds, ₹92.14 crore, had not been deployed by September 30, 2026. The fixed-deposit placement preserves the disclosed unutilised funds while they remain pending use.

Conclusion

Q-Line reported a 5.83% increase in H1 FY27 revenue and a 10.02% rise in EBITDA, with margin expanding to 26.00%. However, profit after tax declined to ₹19.60 crore, making the gap between operating performance and bottom-line performance the central feature of the results.

Investors will watch the company's subsequent financial disclosures for progress in revenue, EBITDA and profit after tax, as well as updates on the utilisation of the ₹92.14 crore in IPO proceeds that remained in fixed deposits as of September 30, 2026.